R. Balakrishnan

Describes accounting theory and the dubious practices that have emerged in recent years, urging reform to restore the integrity of the accounting profession

A NEW YORK TIMES BESTSELLER * New York Times Notable Book * Best Book of the Year: New York Public Library, Kirkus Reviews, Science Friday With a new postscript by the author From an award-winning journalist, an explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers on a global scale—The Jungle for pharmaceuticals Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban’s Bottle of Lies exposes the deceit behind generic-drug manufacturing—and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings? A decade-long investigation with international sweep, high-stakes brinkmanship and big money at its core, Bottle of Lies reveals how the world’s greatest public-health innovation has become one of its most astonishing swindles.

In 2004, Dinesh Thakur, a senior employee of Ranbaxy, then India s largest pharma company, discovered a terrible secret. Ranbaxy had been fabricating the test results of their drugs,endangering millions of patients. Thakur resigned and became a whistleblower to the US Food and Drug Administration, one of the regulators Ranbaxy had been lying to, and ultimately brought the multibillion-dollar behemoth to its knees. This is the sensational account of the high-stakes chase to bring Ranbaxy to book and the fall from grace of one of corporate India s biggest success stories.But the rot in Indian pharma isn t confined to Ranbaxy alone. In this book, investigative journalist Katherine Eban relies on over 20,000 FDA documents and interviews with over 240 people to show how fraud and trickery are deeply entrenched in much of the industry in India, and raises troubling questions about some of its biggest names Wockhardt, Dr Reddy s,Glenmark and RPG Life Sciences. Filled with shocking and eye-opening details, this book laysbare the ugly truth of Indian pharma. It will make you view every pill you take with foreboding and suspicion.

Through a bizarre cycle of dying and coming back to life again and again, Jeff Winston receives six chances to change his life, correct previous mistakes, and find the happiness that has long eluded him

Examines the intricacies of balance sheet interpretation in the fields of commerce and industry. The book is designed to act as a learning tool and revisionary aid for students but would be of use to anyone involved in presenting and/or interpreting balance sheets.

Book by